Justin Rohrback
Family · Lancaster, PANPI 1801412465
Payments from drug & device makers
Across 14 payments — averaging $84.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scynexis, Inc.$874
- AbbVie$134
- Pfizer$81
- Therapeuticsmd, Inc.$25
- Exeltis, USA Inc.$24
- Daiichi Sankyo Inc.$20
- plus $29 from 2 others
What the payments were for
- Consulting fees$75063%
- Food & beverage$43737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scynexis, Inc. | 2 | $874 |
| AbbVie | 3 | $134 |
| Pfizer | 4 | $81 |
| Therapeuticsmd, Inc. | 1 | $25 |
| Exeltis, USA Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$1,187 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $52,808 |
| EliquisApixaban | 18 | $15,978 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,397 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,504 |
| Hydroxyzine Hcl | 49 | $1,123 |
| Losartan Potassium | 55 | $611 |
| Ondansetron OdtOndansetron | 28 | $521 |
| Atorvastatin Calcium | 57 | $405 |
| Gabapentin | 32 | $404 |
| Rosuvastatin Calcium | 31 | $381 |
| Omeprazole | 33 | $371 |
| Methylprednisolone | 41 | $316 |
| Cyclobenzaprine Hcl | 51 | $311 |
| Quetiapine Fumarate | 13 | $254 |
| Furosemide | 40 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $15,97818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.
Other family in Lancaster
- Heidi Kling-NewnamLancaster$30K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.